Compare Abeona Therapeutics Inc (ABEO) vs Spotify Technology (SPOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Spotify Technology — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Spotify Technology trades at $488.95 (market cap $101.57B). The key difference: Spotify Technology is far larger — about 272.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| ABEO | SPOT | |
|---|---|---|
Market Cap | $373.32M | $101.57B |
Sector | Health | Media |
52-Week High | $7.23 | $738.53 |
52-Week Low | $4.17 | $412.75 |
Enterprise Value | $228.22M | $92.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Spotify (SPOT) trades at $493.95, up 1.64% with a bullish technical outlook. The stock shows strong fundamentals with revenue growth from $11.7B in 2022 to $17.2B in 2025 and net income turning positive to $2.2B. Analyst consensus is bullish with a $623 price target, supported by recent earnings beats. Key resistance is near $499, while support holds at $477.
Outlook remains positive driven by margin expansion and platform diversification, but risks include competition and market volatility. The stock offers growth potential with a 26% upside to consensus target, though investors should monitor execution on profitability goals amid rising content costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
